Literature DB >> 4096740

Antitumor activity of 1.3-diketonato zirconium (IV) and hafnium (IV) complexes.

B K Keppler, K Michels.   

Abstract

Ten six-coordinate dihalogenobis (1.3-diketonato)zirconium (IV) and hafnium (IV) complexes as well as seven halogenotris(1.3-diketonato) zirconium(IV) and hafnium(IV) species were prepared and characterized by their elemental analysis, IR- and NMR-spectra. Their antitumor activity was tested using the intraperitoneally transplanted Sarcoma 180 tumor system in mice. Cisplatin was used in several doses as positive control compound. Seven complexes were highly active. The ratio of median survival time of treated to untreated control animals ranged up to 3 (T/C = 300%; the experiment was interrupted after that time) for these compounds. Significance according to Kruskal-Wallis test, long-time survivors, and animals which are dead on day 5 and day 30 are given. The possible mechanism of action compared to cisplatin is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4096740

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

1.  Efficacy of beta-diketonato complexes of titanium, zirconium, and hafnium against chemically induced autochthonous colonic tumors in rats.

Authors:  H Bischoff; M R Berger; B K Keppler; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

2.  Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane.

Authors:  T Schilling; K B Keppler; M E Heim; G Niebch; H Dietzfelbinger; J Rastetter; A R Hanauske
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 3.  [Cytostatic non-platinum metal complexes: new perspectives for the treatment of cancer?].

Authors:  P Köpf-Maier
Journal:  Naturwissenschaften       Date:  1987-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.